Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gunnarsson

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Neurology|August 11, 2021
Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG StudyMalin Petersson, Amalia Feresiadou, Daniel Jons, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 6, 2023
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damageDaniel Jons, Viktor Grut, Tomas Bergström, et al.
JAMA Neurology|October 8, 2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesGustavo Luna, Peter Alping, Joachim Burman, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 21, 2014
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experienceJoachim Burman, Ellen Iacobaeus, Anders Svenningsson, et al.
Neurology|June 10, 2025
Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG StudyMalin Petersson, Daniel Jons, Amalia Feresiadou, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 9, 2023
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapyElisa Longinetti, Simon Englund, Joachim Burman, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohortSimon Englund, Marie Kierkegaard, Joachim Burman, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Neurology|August 11, 2021
Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG StudyMalin Petersson, Amalia Feresiadou, Daniel Jons, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 6, 2023
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damageDaniel Jons, Viktor Grut, Tomas Bergström, et al.
JAMA Neurology|October 8, 2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesGustavo Luna, Peter Alping, Joachim Burman, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 21, 2014
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experienceJoachim Burman, Ellen Iacobaeus, Anders Svenningsson, et al.
Neurology|June 10, 2025
Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG StudyMalin Petersson, Daniel Jons, Amalia Feresiadou, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 9, 2023
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapyElisa Longinetti, Simon Englund, Joachim Burman, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohortSimon Englund, Marie Kierkegaard, Joachim Burman, et al.
Pageof 4